Cerivastatin
As of the edition of 20 October 2026, Cerivastatin is a small molecule: withdrawn from the market in 2001; acts on HMGCR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2001
- Kind
- Small molecule
- Brand name
- Baycol
- First approved
- 26 June 1997 (US)
- Approvals on record
- 6 in 1 region
- Holder of the most recent approval
- Bayer
- Withdrawn from market
- 1 January 2001 (worldwide)
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Cerivastatin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | P04035 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bayer | Originator and Applicant | 1997 to now |